Molecular Degrader Optimization AlphaLISA Assay: A degrader of interest interacts with both PARP and CRBN, bringing them in proximity
Step 4: Begin your transformation
Hellstrom PM, Gryback P, Jacobsson H
Based on the summarized evidence, we also critically discuss the limitations and propose future directions that are expected to fill current research and clinical gaps
Consider proactively contacting patients who are eligible for funded treatment, including Mori and Pacific patients, and those with renal or cardiovascular complications This MedCase was written by Dr Vicki Mount, BSC/BCom, MBChB, MRNZCGP, DipPaeds, with expert review by Dr Ryan Paul (BHB, MBChB, FRACP, PhD) References Recognition of Learning Activities Don't forget to log your time with The Royal New Zealand College of General Practitioners portal for recognition of learning activities.